German law makers seek to ease reimbursement for advanced therapies

15 June 2021 - Advanced therapy trade group The Alliance for Regenerative Medicine has highlighted the passage of a new ...

Read more →

Bluebird’s withdrawal of therapy from Germany could chill talks over gene therapy prices across Europe

22 April 2021 - When Bluebird Bio secured European approval for its gene therapy to treat beta thalassaemia in 2019, ...

Read more →

Novartis to discontinue sales of Piqray in Germany

21 April 2021 - The sale of Piqray (alpelisib) will be discontinued by Novartis in accordance with Section 4 (7) ...

Read more →

Germany to restrict AstraZeneca use in under-60s over clots

30 March 2021 - German health officials have agreed to restrict the use of AstraZeneca’s coronavirus vaccine in people under 60, ...

Read more →

Early benefit assessment - the whole spectrum

19 March 2021 - IQWiG evaluated a total of 24 manufacturer dossiers punctually for the dates March 1 and March 15.  ...

Read more →

Nusinersen in spinal muscular atrophy: indication of considerable added benefit in children with an early onset of the disease

1 March 2021 - The treatment delays permanent ventilation of the children and extends life. In addition, the children develop more ...

Read more →

Dapagliflozin in chronic heart failure: hint of added benefit

1 March 2021 - Diabetes drug is also effective in symptomatic chronic heart failure with reduced pump function. However, the additional ...

Read more →

Clinical relevance of patient-reported outcomes: new threshold proves to be practical

18 February 2021 - Current examples show that the 15% threshold newly set by IQWiG for the recognition of responder analyses ...

Read more →

Germans turn backs on AstraZeneca vaccine

22 February 2021 - Germany’s vaccination program is in trouble, with people failing to keep appointments if they are going ...

Read more →

Germany moves to exclude seniors from AstraZeneca’s COVID-19 vaccine

28 January 2021 - Ahead of its expected approval for use by Europe’s medicines regulator Friday, Germany’s vaccine committee has recommended ...

Read more →

Ibrutinib with rituximab in previously untreated chronic lymphocytic leukaemia: indication of added benefit over FCR

4 January 2020 - The new drug combination prolongs overall survival in patients in good general health. No study data are ...

Read more →

Secukinumab in children with plaque psoriasis: study unsuitable for benefit assessment

3 December 2020 - Inappropriate treatment in the control arm makes fair comparison impossible. ...

Read more →

IQWiG publishes 1,000th report

2 December 2020 - In the 16th year of its existence, IQWiG has published its 1,000th report: a dossier assessment ...

Read more →

Trifarotene in moderate acne: no study data for the assessment of the added benefit

16 November 2020 - Only studies with placebo comparisons despite many affected people and existing treatment alternatives. ...

Read more →

IQWiG publishes a new version of its general methods

5 November 2020 - New features include the investigation of volume-outcome relationships and different mean observation times in clinical studies. ...

Read more →